Publications

  • Ugarte A, Gil-Bea F, García-Barroso C, Cedazo-Minguez A, Ramírez MJ, Franco R, García-Osta A, Oyarzabal J, Cuadrado-Tejedor M. Decreased levels of cGMP in CSF are associated with cognitive decline and amyloid pathology in Alzheimer's disease. Neuropathol Appl Neurobiol. 2015 Jun;41(4):471-82.

  • Pascual-Lucas M, Viana da Silva S, Di Scala M, Garcia-Barroso C, González-Aseguinolaza G, Mulle C, Alberini CM, Cuadrado-Tejedor M, Garcia-Osta A. Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Mol Med. 2014, 6 (10):1246-62.

  • Zamarbide M, Etayo-Labiano I, Ricobaraza A, Martínez-Pinilla E, Aymerich MS, Luis Lanciego J, Pérez-Mediavilla A, Franco R. GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells. Hippocampus. 2014 Jul;24(7):733-9. doi: 10.1002/hipo.22263. Epub 2014 Feb 27.

  • Zamarbide M, Martinez-Pinilla E, Ricobaraza A, Aragón T, Franco R, Pérez-Mediavilla A. Phenyl acyl acids attenuate the unfolded protein response in tunicamycin-treated neuroblastoma cells. PLoS One. 2013 Aug 15;8(8

  • García-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, Sallés J, Lanciego JL, Oyarzabal J, Franco R, Cuadrado-Tejedor M, García-Osta A. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology. 2013; 64:114-23

  • Ricobaraza A, Cuadrado-Tejedor M, Marco S, Perez-Otaño I, GARCIA-OSTA  A. Phenylbutyrate rescues spine loss associated with memory deficits in a mouse model of  Alzheimer's disease. Hippocampus. 2012; 22(5):1040-50.

  • Ricobaraza A, Cuadrado-Tejedor M, Pérez-Mediavilla A, Frechilla D, Del Río J, García-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology. 2009;34(7):1721-32. 



"We try to identify the factors that cause the neurodegenerative process in order to design new experimental strategies that enable us to detect and treat the disease in its early stages" , Dra. Isabel Pérez-Otaño, Program Director.

More information:

Contact

Contact:
Cristina Canciani
Avda. Pío XII, 53
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 2013
canciani@unav.es